Protective Mechanism of Stem Cells from Human Exfoliated Deciduous Teeth in Treating Spinal Cord Injury
Tomoya Nishii,Koji Osuka,Yusuke Nishimura,Yusuke Ohmichi,Mika Ohmichi,Chiharu Suzuki,Yoshitaka Nagashima,Takahiro Oyama,Takashi Abe,Hiroyuki Kato,Ryuta Saito,Takahiro Oyama,Hiroyuki Kato
DOI: https://doi.org/10.1089/neu.2023.0251
IF: 4.869
2024-01-09
Journal of Neurotrauma
Abstract:Spinal cord injury (SCI) induces devastating permanent deficits. Recently, cell transplantation therapy has become a notable treatment for SCI. Although stem cells from human exfoliated deciduous teeth (SHED) are an attractive therapy, their precise mechanism of action remains to be elucidated. In this study, we explored one of the neuroprotective mechanisms of SHED treatment at the subacute stage after SCI. We used a rat clip compression SCI model. The animals were randomly divided into three groups: SCI, SCI + PBS and SCI + SHED. The SHED or PBS intramedullary injection was administered immediately after SCI. After SCI, we explored the effects of SHED on motor function, as assessed by the Basso, Beattie and Bresnahan (BBB) score and the inclined plane method, the signal transduction pathway, especially the Janus kinase (JAK) and the signal transducer and activator of transcription 3 (STAT3) pathway, the apoptotic pathway and the expression of neurocan, one of the chondroitin sulfate proteoglycans. SHED treatment significantly improved functional recovery from day 14 relative to the controls. Western blot analysis showed that SHED significantly reduced the expression of GFAP and phosphorylated STAT3 (p-STAT3) at Tyr705 on day 10 but not on day 5. However, SHED had no effect on the expression levels of iba-1 on days 5 or 10. Immunohistochemistry revealed that p-STAT3 at Tyr705 was mainly expressed in GFAP-positive astrocytes on day 10 after SCI, and its expression was reduced by administration of SHED. Moreover, SHED treatment significantly induced expression of cleaved caspase 3 in GFAP-positive astrocytes only in the epicenter lesions on day 10 after SCI but not on day 5. The expression of neurocan was also significantly reduced by SHED injection on day 10 after SCI. Our results show that SHED plays an important role in reducing astrogliosis and glial scar formation between days 5 and 10 after SCI, possibly via apoptosis of astrocytes, ultimately resulting in improvement in neurological functions thereafter. Our data revealed one of the neuroprotective mechanisms of SHED at the subacute stage after SCI, which improved functional recovery after SCI, a serious condition.
neurosciences,clinical neurology,critical care medicine
What problem does this paper attempt to address?